Cargando…
The Histone Deacetylase Inhibitor ITF2357 (Givinostat) Targets Oncogenic BRAF in Melanoma Cells and Promotes a Switch from Pro-Survival Autophagy to Apoptosis
Histone deacetylase inhibitors (HDACI) are epigenetic compounds that have been widely considered very promising antitumor agents. Here, we focus on the effects of the pan-HDAC inhibitor ITF2357 (Givinostat) in comparison with SAHA (Vorinostat) in melanoma cells bearing BRAF V600E oncogenic mutation....
Autores principales: | Celesia, Adriana, Notaro, Antonietta, Franzò, Marzia, Lauricella, Marianna, D’Anneo, Antonella, Carlisi, Daniela, Giuliano, Michela, Emanuele, Sonia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405675/ https://www.ncbi.nlm.nih.gov/pubmed/36009541 http://dx.doi.org/10.3390/biomedicines10081994 |
Ejemplares similares
-
Oncogenic BRAF and p53 Interplay in Melanoma Cells and the Effects of the HDAC Inhibitor ITF2357 (Givinostat)
por: Celesia, Adriana, et al.
Publicado: (2023) -
Analysis of Givinostat/ITF2357 Treatment in a Rat Model of Neonatal Hypoxic-Ischemic Brain Damage
por: Pawelec, Paulina, et al.
Publicado: (2022) -
Inhibition of the Autophagy Pathway Synergistically Potentiates the Cytotoxic Activity of Givinostat (ITF2357) on Human Glioblastoma Cancer Stem Cells
por: Angeletti, Francesca, et al.
Publicado: (2016) -
Histone deacetylase inhibitor ITF2357 leads to apoptosis and enhances doxorubicin cytotoxicity in preclinical models of human sarcoma
por: Di Martile, Marta, et al.
Publicado: (2018) -
Long non-coding RNA H19 enhances the pro-apoptotic activity of ITF2357 (a histone deacetylase inhibitor) in colorectal cancer cells
por: Zichittella, Chiara, et al.
Publicado: (2023)